$AXGN
Axogen, Inc. Stock $axgn

$axgn Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000110465914017051 Filed on March 06, 2014

Income Statement

Concept	2014 Q1	2013	2012 Q4
Revenue	$3.138M	$10.95M	$2.040M
YoY Change	46.45%	42.33%	50.0%
Cost Of Revenue	$701.3K	$2.440M	$480.0K
YoY Change	25.18%	24.36%	-9.43%
Gross Profit	$2.437M	$8.508M	$1.570M
YoY Change	53.98%	48.48%	89.16%
Gross Profit Margin	77.65%	77.71%	76.96%
Selling, General & Admin	$4.615M	$15.97M	$3.420M
YoY Change	31.9%	31.97%	40.74%
% of Gross Profit	189.4%	187.77%	217.83%
Research & Development	$812.6K	$2.125M	$370.0K
YoY Change	99.69%	48.93%	-36.21%
% of Gross Profit	33.35%	24.98%	23.57%
Depreciation & Amortization	$33.94K	$79.23K	-$80.00K
YoY Change	46.69%	-57.8%	-188.89%
% of Gross Profit	1.39%	0.93%	-5.1%
Operating Expenses	$5.428M	$18.10M	$3.800M
YoY Change	38.96%	33.76%	26.25%
Operating Profit	-$2.991M	-$9.592M	-$2.230M
YoY Change	28.73%	22.95%	2.29%
Interest Expense	$1.191M	$4.820M	-$1.830M
YoY Change	11.59%	246.41%	1043.75%
% of Operating Profit
Other Income/Expense, Net	-$1.248M	-$4.965M	$10.00K
YoY Change	12.07%	110.88%	-50.0%
Pretax Income	-$4.240M	-$14.56M	-$4.040M
YoY Change	23.26%	43.33%	88.79%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.240M	-$14.56M	-$4.040M
YoY Change	23.33%	54.57%	88.79%
Net Earnings / Revenue	-135.09%	-132.97%	-198.04%
Basic Earnings Per Share
Diluted Earnings Per Share	-$244.0K	-$1.081M	-$363.6K
COMMON SHARES
Basic Shares Outstanding	17.37M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.80M	$20.10M	$13.90M
YoY Change	50.0%	44.6%	69.51%
Cash & Equivalents	$16.81M	$20.10M	$13.91M
Short-Term Investments
Other Short-Term Assets	$200.0K	$300.0K	$200.0K
YoY Change	100.0%	50.0%	100.0%
Inventory	$3.466M	$3.400M	$3.151M
Prepaid Expenses
Receivables	$1.965M	$1.900M	$1.050M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$22.43M	$25.70M	$18.30M
YoY Change	41.1%	40.44%	67.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$543.2K	$400.0K	$108.5K
YoY Change	443.23%	300.0%	-45.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.000M	$1.100M	$1.300M
YoY Change	-16.67%	-15.38%	333.33%
Total Long-Term Assets	$2.133M	$2.000M	$1.935M
YoY Change	6.67%	5.26%	20.92%
TOTAL ASSETS
Total Short-Term Assets	$22.43M	$25.70M	$18.30M
Total Long-Term Assets	$2.133M	$2.000M	$1.935M
Total Assets	$24.57M	$27.70M	$20.23M
YoY Change	37.25%	37.13%	61.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.500M	$1.500M
YoY Change		0.0%	-6.25%
Accrued Expenses	$1.900M	$600.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$1.923M	$2.100M	$1.480M
YoY Change	37.35%	40.0%	-26.01%
LONG-TERM LIABILITIES
Long-Term Debt	$26.26M	$25.40M	$21.58M
YoY Change	17.21%	17.59%	390.46%
Other Long-Term Liabilities	$100.0K	$100.0K
YoY Change
Total Long-Term Liabilities	$26.26M	$25.50M	$21.58M
YoY Change	17.21%	18.06%	390.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.923M	$2.100M	$1.480M
Total Long-Term Liabilities	$26.26M	$25.50M	$21.58M
Total Liabilities	$28.26M	$27.50M	$23.06M
YoY Change	18.25%	19.05%	260.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$76.65M		-$57.85M
YoY Change
Common Stock	$72.95M		$55.02M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.693M	$100.0K	-$2.829M
YoY Change
Total Liabilities & Shareholders Equity	$24.57M	$27.70M	$20.23M
YoY Change	37.25%	37.13%	61.84%

Cashflow Statement

Concept	2014 Q1	2013	2012 Q4
OPERATING ACTIVITIES
Net Income	-$4.240M	-$14.56M	-$4.040M
YoY Change	23.33%	54.57%	88.79%
Depreciation, Depletion And Amortization	$33.94K	$79.23K	-$80.00K
YoY Change	46.69%	-57.8%	-188.89%
Cash From Operating Activities	-$3.150M	-$10.44M	-$3.370M
YoY Change	18.87%	20.55%	53.88%
INVESTING ACTIVITIES
Capital Expenditures	$195.5K	$178.8K	-$10.00K
YoY Change	651.65%	268.92%	-75.0%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$200.0K	-$240.0K	-$10.00K
YoY Change	233.33%	84.62%	-75.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$16.78M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	90.00K	16.85M	12.85M
YoY Change		16.13%	-11781.82%
NET CHANGE
Cash From Operating Activities	-3.150M	-10.44M	-3.370M
Cash From Investing Activities	-200.0K	-240.0K	-10.00K
Cash From Financing Activities	90.00K	16.85M	12.85M
Net Change In Cash	-3.260M	6.170M	9.470M
YoY Change	20.3%	7.87%	-504.7%
FREE CASH FLOW
Cash From Operating Activities	-$3.150M	-$10.44M	-$3.370M
Capital Expenditures	$195.5K	$178.8K	-$10.00K
Free Cash Flow	-$3.345M	-$10.62M	-$3.360M
YoY Change	25.02%	21.94%	56.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-2829441	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27684270	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57848893	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	136633	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20069750	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13907401	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1893699	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1050089	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	3398438	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	3151109	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	296719	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	187256	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	25658606	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	18295855	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	381689	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	108534	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	570396	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	573731	USD
CY2013Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	1073579	USD
CY2012Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	1252443	USD
CY2013Q4	us-gaap	Assets Assets	27684270	USD
CY2012Q4	us-gaap	Assets Assets	20230563	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2083942	USD
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1479752	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2098060	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1479752	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	25363695	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21580252	USD
CY2013Q4	us-gaap	Liabilities Liabilities	27547637	USD
CY2012Q4	us-gaap	Liabilities Liabilities	23060004	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	173395	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	111226	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	72369016	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	54908226	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72405778	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	671887	USD
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17373620	shares
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15652	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	73326	USD
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q2	dei	Entity Public Float EntityPublicFloat	25236771	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20230563	USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17339561	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11122573	shares
CY2013	us-gaap	Revenues Revenues	10947361	USD
CY2012	us-gaap	Revenues Revenues	7691704	USD
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2439818	USD
CY2012	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1961877	USD
CY2013	us-gaap	Gross Profit GrossProfit	8507543	USD
CY2012	us-gaap	Gross Profit GrossProfit	5729827	USD
CY2013	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10259153	USD
CY2012	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6883953	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2125476	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1427211	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5715119	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5220599	USD
CY2013	us-gaap	Costs And Expenses CostsAndExpenses	18099748	USD
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	13531763	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-9592205	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-7801936	USD
CY2013	us-gaap	Interest Expense InterestExpense	4819708	USD
CY2012	us-gaap	Interest Expense InterestExpense	1391342	USD
CY2013	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	178864	USD
CY2012	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	986844	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	33892	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23972	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4964680	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2354214	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14556885	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10156150	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-738192	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-14556885	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-9417958	USD
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13499793	shares
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11089425	shares
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.08
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
CY2013	dei	Entity Registrant Name EntityRegistrantName	AxoGen, Inc.
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	14118	USD
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0000805928
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	6071471	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	495077	USD
CY2012	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	21375	USD
CY2012	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	14999	USD
CY2012	axgn	Adjustments To Additional Paid In Capital Fractional Shares AdjustmentsToAdditionalPaidInCapitalFractionalShares	58	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16777746	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	79232	USD
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	187749	USD
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	59100	USD
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	127080	USD
CY2013	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	9424	USD
CY2012	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	129667	USD
CY2012	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-147826	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	178864	USD
CY2012	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	352667	USD
CY2012	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	161529	USD
CY2013	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	58617	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	671887	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	495077	USD
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	21375	USD
CY2012	axgn	Cancellation Of Shares CancellationOfShares	14999	USD
CY2013	us-gaap	Paid In Kind Interest PaidInKindInterest	3783443	USD
CY2012	us-gaap	Paid In Kind Interest PaidInKindInterest	780252	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	902227	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	252435	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	247329	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1390570	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	109463	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	53757	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	430579	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-105348	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	100000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10444758	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8661858	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	178776	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48459	USD
CY2013	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	65189	USD
CY2012	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	78825	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-243965	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-127284	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16777746	USD
CY2012	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	161292	USD
CY2012	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1309834	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	73326	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15652	USD
CY2012	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	58	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	16851072	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	14505762	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6162349	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5716620	USD
CY2013	us-gaap	Interest Paid InterestPaid	1030219	USD
CY2012	us-gaap	Interest Paid InterestPaid	649108	USD
CY2012	us-gaap	Notes Reduction NotesReduction	4838706	USD
CY2013	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">1.</font></b><font style="FONT-SIZE: 3pt;" size="1">                                     </font> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Basis of Presentation</font></b></p> <p style="TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The accompanying consolidated financial statements include the accounts of AxoGen, Inc. (the “Company” or “AxoGen”) and its wholly owned subsidiary AxoGen Corporation (“AC”) as of December 31, 2013 and December 31, 2012 and for the years then ended. The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> </div>
CY2013	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">2.</font></b><font style="FONT-SIZE: 3pt;" size="1">                                     </font> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Organization and Business</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><b><u><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Business Summary</font></u></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company is a leading medical technology company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of muscle function and/or feeling. In order to improve the options available for the surgical repair and regeneration of peripheral nerves, the Company has developed and licensed, patented and patent pending regenerative medicine technologies. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that the Company believes will define their product categories. AxoGen’s products offer a full suite of surgical nerve repair solutions including Avance</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> Nerve Graft, the only off-the-shelf commercially available processed nerve allograft human nerve tissue obtained from a donor for bridging severed nerves without the comorbidities of an autograft second surgical site, such resulting in a loss of feeling where the nerve was removed and potential pain at the donor site. The Company’s AxoGuard</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> line of products are derived from pig tissue and are natural scaffolds of the body called ExtraCellular Matrix, or ECM.  AxoGuard</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> Nerve Connector is used to facilitate the tensionless repair of severed nerves, and AxoGuard</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> Nerve Protector is used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> </div>
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	177000	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><u><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates</font></u></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 13.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> <p style="TEXT-INDENT: 13.5pt; MARGIN: 0in 0in 0pt;"> </p> </div>
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	48000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	48000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	48000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	48000	USD
CY2013Q4	axgn	Reserve For Accounts Receivable Deemed Uncollectible Percentage ReserveForAccountsReceivableDeemedUncollectiblePercentage	1.00	pure
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2131336	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2143176	USD
CY2013Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	235966	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	145156	USD
CY2013Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1031136	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	862777	USD
CY2013Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	382545	USD
CY2012Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	537798	USD
CY2012	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	169887	USD
CY2013	us-gaap	Advertising Expense AdvertisingExpense	37000	USD
CY2012	us-gaap	Advertising Expense AdvertisingExpense	56000	USD
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8315	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.172	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0079	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0061	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2013	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2012	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1111000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1581536	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1502304	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	308457	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	261928	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	48000	USD
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	25363695	USD
CY2012Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	21580252	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	671887	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	495077	USD
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1233000	USD
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y22D
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23075700	USD
CY2013Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	500	USD
CY2013Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	144000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	101500	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23321700	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	84100	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	-121000	USD
CY2013Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	-36900	USD
CY2013Q4	axgn	Deferred Tax Assets Liabilities DeferredTaxAssetsLiabilities	23358600	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23358600	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18182000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	2800	USD
CY2012Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	365600	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	52300	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18602700	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	154900	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	51700	USD
CY2012Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	206600	USD
CY2012Q4	axgn	Deferred Tax Assets Liabilities DeferredTaxAssetsLiabilities	18396100	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18396100	USD
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	62000000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4962500	USD
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3015100	USD
CY2013	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03	pure
CY2013	axgn	Defined Contribution Plan Minimum Age Limit For Eligibility To Participate In Plan DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan	18
CY2007	axgn	Defined Contribution Plan Employer Matching Contribution Percent Required Minimum For Three Of First Five Years Of Plan DefinedContributionPlanEmployerMatchingContributionPercentRequiredMinimumForThreeOfFirstFiveYearsOfPlan	0.03	pure
CY2007	axgn	Defined Contribution Plan Employer Matching Contribution Percent Required Minimum Percentage Specified Period DefinedContributionPlanEmployerMatchingContributionPercentRequiredMinimumPercentageSpecifiedPeriod	P5Y
CY2007	axgn	Defined Contribution Plan Employer Matching Contribution Percent Required Minimum Percentage Number Of Years In Specified Period DefinedContributionPlanEmployerMatchingContributionPercentRequiredMinimumPercentageNumberOfYearsInSpecifiedPeriod	3
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	126322	USD
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	102189	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	243000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	243000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	241000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	207000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	197000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	171000	USD
CY2012	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	15961294	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2012	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03	pure
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11122573	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17339561	shares
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8190781	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	85882	USD
CY2013	axgn	Impairment Of Intangible Assets And Goodwill ImpairmentOfIntangibleAssetsAndGoodwill	9424	USD
CY2012	axgn	Impairment Of Intangible Assets And Goodwill ImpairmentOfIntangibleAssetsAndGoodwill	299654	USD
CY2013	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	173611	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	58617	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	203380	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	137329	USD
CY2013Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	417825	USD
CY2012Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	121746	USD

Files In Submission

Name	View Source	Status
0001104659-14-017051-index-headers.html	Edgar Link	pending
0001104659-14-017051-index.html	Edgar Link	pending
0001104659-14-017051.txt	Edgar Link	pending
0001104659-14-017051-xbrl.zip	Edgar Link	pending
a14-5254_110k.htm	Edgar Link	pending
a14-5254_1ex10d10d3.htm	Edgar Link	pending
a14-5254_1ex10d18.htm	Edgar Link	pending
a14-5254_1ex21d1.htm	Edgar Link	pending
a14-5254_1ex23d1.htm	Edgar Link	pending
a14-5254_1ex31d1.htm	Edgar Link	pending
a14-5254_1ex31d2.htm	Edgar Link	pending
a14-5254_1ex32d1.htm	Edgar Link	pending
axgn-20131231.xml	Edgar Link	completed
axgn-20131231.xsd	Edgar Link	pending
axgn-20131231_cal.xml	Edgar Link	unprocessable
axgn-20131231_def.xml	Edgar Link	unprocessable
axgn-20131231_lab.xml	Edgar Link	unprocessable
axgn-20131231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g52541bgi001.jpg	Edgar Link	pending
g52541bgi002.jpg	Edgar Link	pending
g52541kk01i001.gif	Edgar Link	pending
g52541kk01i002.gif	Edgar Link	pending
g52541kk01i003.gif	Edgar Link	pending
g52541kk01i004.gif	Edgar Link	pending
g52541kk01i005.gif	Edgar Link	pending
g52541kk01i006.gif	Edgar Link	pending
g52541kk01i007.gif	Edgar Link	pending
g52541kk01i008.gif	Edgar Link	pending
g52541kk01i009.gif	Edgar Link	pending
g52541kk01i010.gif	Edgar Link	pending
g52541kk01i011.gif	Edgar Link	pending
g52541kk01i012.gif	Edgar Link	pending
g52541kk01i013.gif	Edgar Link	pending
g52541kk01i014.gif	Edgar Link	pending
g52541kk01i015.gif	Edgar Link	pending
g52541kk01i016.gif	Edgar Link	pending
g52541kk01i017.gif	Edgar Link	pending
g52541kk01i018.gif	Edgar Link	pending
g52541kk01i019.gif	Edgar Link	pending
g52541kk01i020.gif	Edgar Link	pending
g52541kk01i021.gif	Edgar Link	pending
g52541kk03i001.gif	Edgar Link	pending
g52541kk03i002.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AXGN
Axogen, Inc. Stock $axgn

2014 Q1 Form 10-K Financial Statement

#000110465914017051 Filed on March 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AXGN Axogen, Inc. Stock $axgn

2014 Q1 Form 10-K Financial Statement

#000110465914017051 Filed on March 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AXGN
Axogen, Inc. Stock $axgn